Nico van ZandwijkHead of the Department of Thoracic Oncology,

Netherlands Cancer Institute, Amsterdam, The Netherlands

Former secretary and chairman of the European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group

Member of the Board of Directors of the International Association for the Study of Lung Cancer (IASLC)

Member of the Advisory Board of the Thoracic Section of the French National Cancer Institute (INCa)

Is the co-author of more than 180 peer-reviewed international papers and chapters

Will take up the post of inaugural director of a new thoracic oncology institute at the University of Sydney, Australia, inMarch 2008

Netherlands Cancer Institute

Challenges for the first- and second-line treatment of

non-small cell lung cancer

Nico van ZandwijkNetherlands Cancer InstituteAmsterdam, The Netherlands

Thursday 7 February 2008Agenda

14.10 Chair’s openingNico van Zandwijk

14.15 The new kid on the block: bevacizumab in first-line NSCLCNick Thatcher

14.45 First choice in second line: erlotinib in NSCLCRomàn Pérez-Soler

15.15 Discussion

15.30 Coffee break

16.00 Meet the Expert sessions

Lung cancer is the most common form of cancer in the world

Lung

Breast

Bowel

Stomach

Liver

Prostate

Cervix

Oesophagus

Bladder

Leukaemia

Oral cavity

Pancreas

Kidney

Ovary

Uterus

Brain and CNS

Melanoma

Larynx

Thyroid 141,000

159,000

160,200

189,500

198,800

204,500

208,500

232,300

274,300

300,500

300,600

356,600

462,100

493,200

626,200

679,000

933,900

1,023,200

1,151,300

1,352,100

Non-Hodgkin’s lymphoma

Ferlay J, et al. Globocan 2002: Cancer incidence, mortality and prevalence worldwide

American Cancer Society: cancer facts and figures 2007

213,380

37,170

180,510

51,190

112,340

160,390

12,890

33,370

52,18040,910

Incidence

Mortality

Lung cancer has highincidence and mortality

Est

imat

ed n

ew c

ases

/d

eath

s in

th

e U

SA

(p

er y

ear)

250,000

200,000

150,000

100,000

50,000

0 Breast Colon Pancreas Kidney Lung

Advanced NSCLC: what are thetreatment goals for patients?

‘Longer life’– improved overall survival

‘Better life’– agents for patients who are not suitable for

chemotherapy– improvement of disease-related symptoms– better-tolerated regimens; reduced toxicity– prolonged time to disease progression– improved disease control rate– improved quality of life

NSCLC = non-small cell lung cancer

NSCLC: what are the challengesthat we face in the next decade?

Determine how new agents can be best used in conjunction with current treatment modalities

Determine how best to tailor therapy for the patient

Expanding therapeutic options without increased toxicity for elderly and performance status 2 patients

Expanding the eligible patient population for novel targeted agents

Treatment options beyond second line